Regulators Expected To Approve Innovative Schizophrenia Treatment From Bristol Myers, Karuna - Bristol-Myers Squibb ( NYSE:BMY )
Some 3 million Americans, and approximately 24 million people worldwide, are likely looking forward to a pivotal date next month in which U.S. regulators are expected to decide on whether to approve a new - more innovative - schizophrenia drug. What Happened: The U.S.
| Ticker |
Sentiment |
Impact |
|
LLY
|
Neutral
|
24 %
|
|
ABBV
|
Somewhat Bullish
|
24 %
|
|
DSSMY
|
Neutral
|
24 %
|
|
BMY
|
Neutral
|
24 %
|
|
NBIX
|
Somewhat Bullish
|
24 %
|
